|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang ZY: Hepatocellular carcinoma-cause,
treatment and metastasis. World J Gastroenterol. 7:445–454. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang XD, Wang Y and Ye LH: Hepatitis B
virus X protein accelerates the development of hepatoma. Cancer
Biol Med. 11:182–190. 2014.PubMed/NCBI
|
|
4
|
Wang Y, Cui F, Lv Y, Li C, Xu X, Deng C,
Wang D, Sun Y, Hu G, Lang Z, et al: HBsAg and HBx knocked into the
p21 locus causes hepatocellular carcinoma in mice. Hepatology.
39:318–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fyffe C and Falasca M:
3-Phosphoinositide-dependent protein kinase-1 as an emerging target
in the management of breast cancer. Cancer Manag Res. 5:271–280.
2013.PubMed/NCBI
|
|
7
|
Cho JY and Park J: Contribution of natural
inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the
insulin-mediated intracellular signaling cascade. Int J Mol Sci.
9:2217–2230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mora A, Komander D, van Aalten DM and
Alessi DR: PDK1, the master regulator of AGC kinase signal
transduction. Semin Cell Dev Biol. 15:161–170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castel P, Ellis H, Bago R, Toska E, Razavi
P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, et
al: PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation
and confers resistance to PI3Kα inhibition. Cancer Cell.
30:229–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujiwara S, Kawano Y, Yuki H, Okuno Y,
Nosaka K, Mitsuya H and Hata H: PDK1 inhibition is a novel
therapeutic target in multiple myeloma. Br J Cancer. 108:170–178.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wada M, Horinaka M, Yasuda S, Masuzawa M,
Sakai T and Katoh N: PDK1 is a potential therapeutic target against
angiosarcoma cells. J Dermatol Sci. 78:44–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du J, Yang M, Chen S, Li D, Chang Z and
Dong Z: PDK1 promotes tumor growth and metastasis in a spontaneous
breast cancer model. Oncogene. 35:3314–3323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Liu F, Ao P, Li X, Zheng H, Wu D,
Zhang N, She J, Yuan J and Wu X: Correlation of PDK1 expression
with clinicopathologic features and prognosis of hepatocellular
carcinoma. Onco Targets Ther. 9:5597–5602. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Verissimo F and Jordan P: WNK kinases, a
novel protein kinase subfamily in multi-cellular organisms.
Oncogene. 20:5562–5569. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang CL, Cha SK, Wang HR, Xie J and Cobb
MH: WNKs: Protein kinases with a unique kinase domain. Exp Mol Med.
39:565–573. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vitari AC, Deak M, Collins BJ, Morrice N,
Prescott AR, Phelan A, Humphreys S and Alessi DR: WNK1, the kinase
mutated in an inherited high-blood-pressure syndrome, is a novel
PKB (protein kinase B)/Akt substrate. Biochem J. 378:257–268. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun X, Gao L, Yu RK and Zeng G:
Down-regulation of WNK1 protein kinase in neural progenitor cells
suppresses cell proliferation and migration. J Neurochem.
99:1114–1121. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shyamasundar S, Lim JP and Bay BH: miR-93
inhibits the invasive potential of triple-negative breast cancer
cells in vitro via protein kinase WNK1. Int J Oncol. 49:2629–2636.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Costa V, Esposito R, Ziviello C, Sepe R,
Bim LV, Cacciola NA, Decaussin-Petrucci M, Pallante P, Fusco A and
Ciccodicola A: New somatic mutations and WNK1-B4GALNT3 gene fusion
in papillary thyroid carcinoma. Oncotarget. 6:11242–11251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie T, D'Ario G, Lamb JR, Martin E, Wang
K, Tejpar S, Delorenzi M, Bosman FT, Roth AD, Yan P, et al: A
comprehensive characterization of genome-wide copy number
aberrations in colorectal cancer reveals novel oncogenes and
patterns of alterations. PLoS One. 7:e420012012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moniz S and Jordan P: Emerging roles for
WNK kinases in cancer. Cell Mol Life Sci. 67:1265–1276. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kew MC: Epidemiology of chronic hepatitis
B virus infection, hepatocellular carcinoma, and hepatitis B
virus-induced hepatocellular carcinoma. Pathol Biol (Paris).
58:273–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Zhang H and Ye L: Effects of
hepatitis B virus X protein on the development of liver cancer. J
La Clin Med. 147:58–66. 2006.
|
|
25
|
Khaar E, Mukherji A and Kumar V: Akt
augments the oncogenic potential of the HBx protein of hepatitis B
virus by phosphorylation. FEBS J. 279:1220–1230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsieh A, Kim HS, Lim SO, Yu DY and Jung G:
Hepatitis B viral X protein interacts with tumor suppressor
adenomatous polyposis coli to activate Wnt/β-catenin signaling.
Cancer Lett. 300:162–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cha MY, Kim CM, Park YM and Ryu WS:
Hepatitis B virus X protein is essential for the activation of
Wnt/beta-catenin signaling in hepatoma cells. Hepatology.
39:1683–1693. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Waris G, Huh KW and Siddiqui A:
Mitochondrially associated hepatitis B virus X protein
constitutively activates transcription factors STAT-3 and NF-kappa
B via oxidative stress. Mol Cell Biol. 21:7721–7730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teng J, Wang X, Xu Z and Tang N:
HBx-dependent activation of Twist mediates STAT3 control of
epithelium-mesenchymal transition of liver cells. J Cell Biochem.
114:1097–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eser S, Reiff N, Messer M, Seidler B,
Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et
al: Selective requirement of PI3K/PDK1 signaling for Kras
oncogene-driven pancreatic cell plasticity and cancer. Cancer cell.
23:406–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miller TW, Rexer BN, Garrett JT and
Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway:
Role in tumor progression and therapeutic implications in breast
cancer. Breast Cancer Res. 13:2242011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raimondi C and Falasca M: Targeting PDK1
in cancer. Curr Med Chem. 18:2763–2769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin YM, Yun C, Park C, Wang HJ and Cho H:
Expression of hepatitis B virus X protein is closely correlated
with the high periportal inflammatory activity of liver diseases. J
Viral Hepat. 8:322–330. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scortegagna M, Lau E, Zhang T, Feng Y,
Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, et al: PDK1
and SGK3 contribute to the growth of BRAF-mutant melanomas and are
potential therapeutic targets. Cancer Res. 75:1399–1412. 2015.
View Article : Google Scholar : PubMed/NCBI
|
